Anthony Giovinazzo
Chairman chez XORTX THERAPEUTICS INC.
Fortune : 36 237 $ au 31/03/2024
Profil
Anthony J.
Giovinazzo founded Cervelo Pharmaceuticals Ltd.
in 2006, where he worked as Chief Executive Officer from 2006 to 2009.
Mr. Giovinazzo also currently works at XORTX Therapeutics, Inc., as Non-Executive Chairman from 2022, Kalgene Pharmaceuticals, Inc., as Executive Chairman from 2021, Titan Medical, Inc., as Lead Independent Director from 2021, Valo Therapeutics Oy, as Director from 2022, and Institute of Corporate Directors, as Member.
Mr. Giovinazzo also formerly worked at Cita NeuroPharmaceuticals, Inc., as President & Chief Executive Officer, Sunovion CNS Development Canada Ulc, as President & Chief Executive Officer, Cynapsus Therapeutics, Inc., as President, Chief Executive Officer & Director from 2009 to 2017, Sublimity Therapeutics Ltd., as Executive Chairman, Alpha Cognition, Inc., as Executive Chairman, Windfall Geotek, Inc., as Independent Director from 2012 to 2013, ZyVersa Therapeutics Operating, Inc., as Director, ProMIS Neurosciences, Inc., as Independent Director from 2017 to 2020, Pond Technologies Holdings, Inc., as Director from 2020 to 2021, Microbix Biosystems, Inc., as Independent Director from 2020 to 2022, Nordion (Canada), Inc., as Venture Partner, PNO Resources Ltd., as President, Neurotrophic Bioscience, Inc., as President, and Nova Molecular, Inc., as President.
Mr. Giovinazzo received his undergraduate degree in 1978 from McMaster University and Masters Business Admin degree in 1986 from International Institute for Management Development.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
XORTX THERAPEUTICS, INC.
0,48% | 08/03/2024 | 9 625 ( 0,48% ) | 35 613 $ | 31/03/2024 |
TITAN MEDICAL INC.
0,01% | 16/05/2023 | 12 000 ( 0,01% ) | 624 $ | 31/03/2024 |
Postes actifs de Anthony Giovinazzo
| Sociétés | Poste | Début |
|---|---|---|
| TITAN MEDICAL INC. | Director/Board Member | 30/09/2020 |
| XORTX THERAPEUTICS INC. | Chairman | 06/06/2022 |
Kalgene Pharmaceuticals, Inc.
 Kalgene Pharmaceuticals, Inc. Medical/Nursing ServicesHealth Services Kalgene Pharmaceuticals, Inc. develops and focuses on personalized cancer diagnostics and drugs. It offers drugs for epithelial and thyroid cancers. The firm's oncology programs are aimed at improving clinical and survival outcomes through the use of personalized medicine, with a particular focus on bladder, epithelial and thyroid cancers. It serves the biopharmaceutical, research and development and health industries. The company is headquartered in Kingston, Canada. | Chairman | 01/07/2021 |
Institute of Corporate Directors
 Institute of Corporate Directors Miscellaneous Commercial ServicesCommercial Services The Institute of Corporate Directors is a not-for-profit, member-based association that serves as a resource and voice for directors and boards. The non-profit company is based in Toronto, Canada, and has subsidiaries in Canada. The ICD provides thought leadership through various publications and is a unified voice for directors. The Canadian company was founded by Brian J. Gibson, and Rahul K. Bhardwaj has been the CEO of the company since 2016. | Corporate Officer/Principal | 13/09/2010 |
Valo Therapeutics Oy
 Valo Therapeutics Oy Pharmaceuticals: MajorHealth Technology Valo Therapeutics Oy is an immunotherapy company based in Helsinki, FI. The Finnish company is focused on developing innovative immunotherapy approaches against cancer and infectious disease. Valo Therapeutics's lead platform, PeptiCRAd, was developed out of the laboratory of Professor Vincenzo Cerullo at the University of Helsinki. The company is also developing PeptiEnv and PeptiVax, among other neoantigen strategies, in collaboration with Professor Cerullo. The company's PeptiChip technology enables the rapid and accurate identification of tumor antigens. Valo Therapeutics is also developing antigen-coated oncolytic viruses as anti-cancer therapeutic vaccines. The company was founded in 2016, and Paul Grant Higham has been the CEO of the company since 2020. | Director/Board Member | 27/06/2022 |
Anciens postes connus de Anthony Giovinazzo
| Sociétés | Poste | Fin |
|---|---|---|
| MICROBIX BIOSYSTEMS INC. | Director/Board Member | 01/03/2022 |
| POND TECHNOLOGIES HOLDINGS INC. | Director/Board Member | 01/06/2021 |
| PROMIS NEUROSCIENCES, INC. | Director/Board Member | 01/09/2020 |
| CYNAPSUS THERAPEUTICS INC | Chief Executive Officer | 01/03/2017 |
| ░░░░░░░░ ░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
Formation de Anthony Giovinazzo
| McMaster University | Undergraduate Degree |
| International Institute for Management Development | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 6 |
|---|---|
| MICROBIX BIOSYSTEMS INC. | Health Technology |
| WINDFALL GEOTEK INC. | Non-Energy Minerals |
| PROMIS NEUROSCIENCES, INC. | Health Technology |
| TITAN MEDICAL INC. | Health Technology |
| POND TECHNOLOGIES HOLDINGS INC. | Health Technology |
| XORTX THERAPEUTICS INC. | Health Technology |
| Entreprise privées | 14 |
|---|---|
Nordion (Canada), Inc.
 Nordion (Canada), Inc. Pharmaceuticals: MajorHealth Technology Nordion (Canada), Inc. provides drug discovery and development research services. It specializes in health science, gamma irradiation, radiopharmaceutical, gamma sterilization, medical isotopes, and production irradiators. The company was founded in 1946 and is headquartered in Ottawa, Canada. | Health Technology |
PNO Resources Ltd.
 PNO Resources Ltd. Other Metals/MineralsNon-Energy Minerals PNO Resources Ltd. engages in the acquisition and exploration of natural resource properties. The company was founded on February 22, 1983 and is headquartered in Vancouver, Canada. | Non-Energy Minerals |
Cita NeuroPharmaceuticals, Inc.
 Cita NeuroPharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Cita Neuro Pharmaceuticals, Inc. develops and commercializes small molecule drugs. Its clinical drug portfolio consists of drugs for Parkinson's disease and neuropathic pain. Cita Neuro Pharmaceuticals was founded in 1997 by Brian Bennett, Roland Boegman, Khem Jha-mandas, James Reynolds and Gregory Thatcher and is headquartered in Mississauga, Canada. | Health Technology |
Cynapsus Therapeutics, Inc.
 Cynapsus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Cynapsus Therapeutics, Inc. operated as a pharmaceutical company, which developed an improved dosing formulation of an approved drug used to treat the symptoms of Parkinson's disease. The company was founded by Andrew Williams and David Hill on January 16, 2004 and was headquartered in Toronto, Canada. | Health Technology |
ZyVersa Therapeutics Operating, Inc.
 ZyVersa Therapeutics Operating, Inc. Pharmaceuticals: MajorHealth Technology ZyVersa Therapeutics Operating, Inc. operates as a specialty pharmaceutical company, which develops and commercializes prescription pharmaceutical products. The firm focuses on developing products for the treatment of men?s health, as well as for other markets where current therapies are suboptimal and underdeveloped. It offers VAR 100, an oral formulation of native testosterone to treat male hypogonadism; and VAR 200 that minimizes and prevents kidney cell damage, and improves focal segmental glomerulosclerosis prognosis. The company was founded by Stephen C. Glover and Shawn M. Titcomb in 2014 and is headquartered in Weston, FL. | Health Technology |
Neurotrophic Bioscience, Inc.
 Neurotrophic Bioscience, Inc. Pharmaceuticals: MajorHealth Technology Neurotrophic Bioscience, Inc. develops pharmaceutical products. | Health Technology |
Nova Molecular, Inc.
 Nova Molecular, Inc. Medical SpecialtiesHealth Technology Part of SignalEnergy, Inc., Nova Molecular, Inc. develops pharmaceutical products. The private company is based in Montréal, Canada. | Health Technology |
Institute of Corporate Directors
Institute of Corporate Directors Miscellaneous Commercial ServicesCommercial Services The Institute of Corporate Directors is a not-for-profit, member-based association that serves as a resource and voice for directors and boards. The non-profit company is based in Toronto, Canada, and has subsidiaries in Canada. The ICD provides thought leadership through various publications and is a unified voice for directors. The Canadian company was founded by Brian J. Gibson, and Rahul K. Bhardwaj has been the CEO of the company since 2016. | Commercial Services |
Cervelo Pharmaceuticals Ltd.
 Cervelo Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Cervelo Pharmaceuticals Ltd. engages in the preparation of pharmaceuticals. It develops drug product candidates for neuropathic, inflammatory, and neurodegenerative diseases. The company was founded by Anthony J. Giovinazzo in 2006 and is headquartered in Mississauga, Canada. | Health Technology |
Sublimity Therapeutics Ltd.
 Sublimity Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Sublimity Therapeutics Ltd. develops and manufactures pharmaceutical products. It engages in the development of gastrointestinal and immunological therapeutics. The firm’s lead product, CyCol, harnesses the powerful efficacy of the known immunosuppressive drug, cyclosporine in a safer format by targeting drug release towards the site of diseased tissue in the colon of patients with ulcerative colitis. Its other products include CyCron, AlloCol, CyLow, oral vaccines and oral peptides. The company was founded by Ivan Coulter in 2003 and is headquartered in Dublin, Ireland. | Health Technology |
Kalgene Pharmaceuticals, Inc.
Kalgene Pharmaceuticals, Inc. Medical/Nursing ServicesHealth Services Kalgene Pharmaceuticals, Inc. develops and focuses on personalized cancer diagnostics and drugs. It offers drugs for epithelial and thyroid cancers. The firm's oncology programs are aimed at improving clinical and survival outcomes through the use of personalized medicine, with a particular focus on bladder, epithelial and thyroid cancers. It serves the biopharmaceutical, research and development and health industries. The company is headquartered in Kingston, Canada. | Health Services |
Sunovion CNS Development Canada Ulc
 Sunovion CNS Development Canada Ulc Pharmaceuticals: MajorHealth Technology Sunovion CNS Development Canada Ulc develops pharmaceuticals products. The company is headquartered in Vancouver, Canada. | Health Technology |
Alpha Cognition, Inc. /old/
 Alpha Cognition, Inc. /old/ Pharmaceuticals: MajorHealth Technology Alpha Cognition, Inc. engages in operation of a biopharmaceutical company focused on the development of novel therapies to treat diseases of the brain and spinal cord. It also provides research programs to find alternative ways of treating Alzheimer’s disease and Amyotrophic Lateral Sclerosis (ALS). The company is headquartered in Vancouver, Canada. | Health Technology |
Valo Therapeutics Oy
Valo Therapeutics Oy Pharmaceuticals: MajorHealth Technology Valo Therapeutics Oy is an immunotherapy company based in Helsinki, FI. The Finnish company is focused on developing innovative immunotherapy approaches against cancer and infectious disease. Valo Therapeutics's lead platform, PeptiCRAd, was developed out of the laboratory of Professor Vincenzo Cerullo at the University of Helsinki. The company is also developing PeptiEnv and PeptiVax, among other neoantigen strategies, in collaboration with Professor Cerullo. The company's PeptiChip technology enables the rapid and accurate identification of tumor antigens. Valo Therapeutics is also developing antigen-coated oncolytic viruses as anti-cancer therapeutic vaccines. The company was founded in 2016, and Paul Grant Higham has been the CEO of the company since 2020. | Health Technology |
